Indeed, in UKB European cohort, we found that 2.9% (48/1641) of all aggressive prostate cancer cases carried a BRCA2 or ATM QV compared to 0.9% (114/12,936) of non-aggressive prostate cancer cases (PFET = 1.46 × 10−10). This evidence concerns the gene BRCA2 and prostate carcinoma.